443TiP Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120)

摘要: BackgroundThe conversion treatment with FOLFOXIRI and bevacizumab (Bev) in patients with RAS mutant (MUT), irresectable metastatic colorectal cancer (mCRC) may lead to secondary surgical and/or ablative interventions, which are associated with improved survival. Data suggest that more patients could undergo secondary interventions than actually reported. The availability might be improved by central monitoring for these options.